HOME >> BIOLOGY >> NEWS
Pan-African Malaria Conference November 17-22 in Arusha, Tanzania

National Institutes of Health, Bethesda, Maryland -- The Fogarty International Center (FIC) of the National Institutes of Health (NIH) announces the Third Pan-African Malaria Conference of the Multilateral Initiative on Malaria (MIM). The MIM conference, now open to members of the media, will be held November 17 to 22, 2002, in Arusha, Tanzania.

The MIM conference will bring together malaria researchers from across Africa and around the world to consider malaria research advances, how to more effectively employ or develop malaria-control strategies, and how to strengthen malaria research training activities. More than 700 malaria researchers and control experts will attend the MIM conference.

MIM is an international alliance of research and public health agencies and African scientists established in 1997 in Dakar, Senegal, at the first Pan-African Malaria Conference. MIM's objectives are to stimulate and support collaborative research to address the needs of public health programs in malaria-endemic countries and to strengthen research capacity in malaria-endemic countries. FIC, which serves as the current MIM Secretariat, organized the conference on behalf of the MIM partners.

Public and private groups are co-sponsoring the conference. Major sponsors include the NIH (the Fogarty International Center, the National Institute of Allergy and Infectious Diseases, the National Institute of Environmental Health Sciences, and the National Library of Medicine), the Bill & Melinda Gates Foundation, GlaxoSmithKline, the German Federal Ministry for Education and Research, the Malaria Vaccine Initiative, the Swiss Development Cooperation, the United States Agency for International Development, the World Health Organization, The Wellcome Trust, and the UK Medical Research Council. A complete list of partners is available on the MIM website at http://mim.nih.gov.

Malaria kills 2.7 million people each year, mo
'"/>

Contact: Irene Edwards
edwardsi@mail.nih.gov
301-496-2075
NIH/Fogarty International Center
16-Oct-2002


Page: 1 2

Related biology news :

1. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
2. Malaria rise in Africa parallels warming trends
3. Multilateral Initiative on Malaria Secretariat to move to Sweden
4. Malaria research and training benefits global community
5. Malaria called failure, puzzle and challenge
6. Multicomponent Malaria Vaccine Shows Promise in Laboratory Tests
7. Christmas Travellers Are Warned Of Malaria Risks
8. Genetic Code Of Chromosome Of Malaria Parasite Deciphered
9. Virginia Tech Scientist Seek Genetic Solution To Malaria
10. Severe Falciparum Malaria Increases In Honduras
11. Curing Malaria, Controlling Mosquitoes Symposium Set For AAAS Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pan African Malaria Conference November Arusha Tanzania

(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: